Possible survival benefit from concomitant beta-but not calcium-antagonist therapy during reperfusion for acute

S G Ellis1, D W Muller, E J Topol

  • 1Department of Internal Medicine, University of Michigan Hospital, Ann Arbor.

Insights

Long-term beta-blocker therapy before myocardial infarction improved in-hospital survival compared to reperfusion alone. Calcium-antagonist therapy showed no survival benefit in this study of acute myocardial infarction patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Long-term beta- or calcium-antagonist therapy may impact survival after myocardial infarction (MI) and reperfusion.
  • Investigating pre-infarction medication effects on in-hospital survival is crucial for patient outcomes.

Purpose of the Study:

  • To test if long-term beta- or calcium-antagonist therapy before myocardial infarction improves in-hospital survival compared to reperfusion alone.

Main Methods:

  • Retrospective analysis of 424 patients undergoing coronary angioplasty within 12 hours of MI symptom onset.
  • Stepwise logistic regression identified independent predictors of in-hospital death.
  • Compared survival rates between patients on beta-blockers, calcium antagonists, and no pre-infarction medication.

Main Results:

  • Beta-blocker use was independently correlated with improved in-hospital survival (0% vs 8% mortality).
  • Calcium-antagonist therapy did not significantly affect survival rates.
  • Patients on beta-blockers had lower heart rate and left ventricular end-diastolic pressure.

Conclusions:

  • Pre-infarction beta-blocker therapy may improve early survival in acute myocardial infarction patients undergoing reperfusion.
  • Calcium-antagonist therapy did not demonstrate a survival benefit in this cohort.
  • Further research is needed to confirm these findings on beta-blocker efficacy.